Cytokinetics, Inc. (CYTK) Posts Q4 Loss of 16c/Share; Guides FY12 Revs
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $67.56 -1.77%
EPS Growth %: +43.1%
Financial Fact:
Total revenues: 59.05M
Today's EPS Names:
ALZN, ASPU, OCCI, More
EPS Growth %: +43.1%
Financial Fact:
Total revenues: 59.05M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q4 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $757 thousand versus the consensus estimate of $5.62 million.
Sees FY12 revenue of $4-$5 million, versus the consensus of $4 million.
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.
Sees FY12 revenue of $4-$5 million, versus the consensus of $4 million.
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- UBS Downgrades Buzzi Unicem SpA (BZU:IM) (BZZUY) to Sell
- Kotak Starts INDO-MIM Ltd (INDOMIM:IN) at Reduce (3)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
